Evidence map›Paper›PMID 35986430›Full record

ArticleActa neuropathologica communications2022

YAP1-MAML2 fusion in a pediatric NF2-wildtype intraparenchymal brainstem schwannoma.

Matthias A Karajannis, Bryan K Li, Mark M Souweidane, Benjamin Liechty, JinJuan Yao, Jamal K Benhamida, Tejus A Bale, Marc K Rosenblum

Open access · goldAbstract readCase Reports
In one paragraph

Article in Acta neuropathologica communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. ZFTA::YAP1-rearranged ependymoma: is still ZFTA or already YAP?Acta neuropathologica communications · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Matthias A KarajannisPediatric Neuro-Oncology Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. karajanm@mskcc.org.ORCID 0000-0002-7151-6528
Bryan K LiPediatric Neuro-Oncology Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Mark M SouweidaneDepartment of Neurosurgery, Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Benjamin LiechtyDepartment of Pathology, Weill Cornell Medicine, New York, NY, USA.
JinJuan YaoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jamal K BenhamidaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tejus A BaleDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Marc K RosenblumDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Memorial Sloan Kettering Cancer Center · USCornell University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Biallelic inactivation of NF2 represents the primary or sole oncogenic driver event in the vast majority of schwannomas. We report on a four-year-old female who underwent subtotal resection of a right medullary intraparenchymal schwannoma. RNA sequencing revealed an in-frame fusion between exon 5 of YAP1 and exon 2 of MAML2. YAP1-MAML2 fusions have previously been reported in a variety of tumor types, but not schwannomas. Our report expands the spectrum of oncogenic YAP1 gene fusions an alternative to NF2 inactivation to include sporadic schwannoma, analogous to what has recently been described in NF2-wildtype pediatric meningiomas. Appropriate somatic and germline molecular testing should be undertaken in all young patients with solitary schwannoma and meningioma given the high prevalence of an underlying tumor predisposition syndrome. In such patients, the identification of a somatic non-NF2 driver alteration such as this newly described YAP1 fusion, can help ascertain the diagnosis of a sporadic schwannoma.

Indexed as

Meningeal NeoplasmsMeningiomaNeurilemmomaNeurofibromatosis 2Brain StemChildChild, PreschoolFemaleGene FusionHumansTrans-ActivatorsTranscription FactorsYAP-Signaling ProteinsMAML2 protein, humanTrans-ActivatorsTranscription FactorsYAP1 protein, humanYAP-Signaling ProteinsMastermind like transcriptional coactivator 2 (MAML2)PediatricSchwannomaYes1 associated transcriptional regulator (YAP1)

Identifiers

PMID35986430
PMCPMC9392329
OpenAlexW4292686159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.